Holen Sie sich die Stockscreener-App
75.52
1.86%
1.38
Schlusskurs vom Vortag:
$74.14
Offen:
$74.34
24-Stunden-Volumen:
2.41M
Relative Volume:
0.88
Marktkapitalisierung:
$14.64B
Einnahmen:
$502.08M
Nettoeinkommen (Verlust:
$-732.94M
KGV:
-19.96
EPS:
-3.7842
Netto-Cashflow:
$-455.50M
1W Leistung:
+3.24%
1M Leistung:
+15.05%
6M Leistung:
+37.84%
1J Leistung:
+129.68%
1-Tages-Spanne:
$73.14
$76.24
1-Wochen-Bereich:
$70.52
$76.24
52-Wochen-Spanne:
$30.08
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
75.52 | 14.37B | 502.08M | -732.94M | -455.50M | -3.7842 |
VRTX
Vertex Pharmaceuticals Inc
|
446.78 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
767.85 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.50 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.28 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.42 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
120,000-share Form 144; BBIO insiders report 10b5-1 sales (BBIO) - Stock Titan
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Strength And Late Stage Pipeline Focus - Yahoo Finance
BridgeBio Pharma (BBIO) Receives Positive Analyst Coverage from RBC Capital | BBIO Stock News - GuruFocus
RBC Initiates BridgeBio Pharma at Outperform, Speculative Risk With $100 Price Target - Moomoo
Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157 - Moomoo
RBC Capital Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $100 - Moomoo
RBC Capital initiates BridgeBio Pharma stock at Outperform with $100 target - Investing.com UK
BridgeBio Submits NDA for BBP-418 in LGMD2I/R9, Potentially the First Approved Therapy for Any Form of Limb-Girdle Muscular Dystrophy - NeurologyLive
(BBIO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Sentiment Watch: Should you buy the dip on BridgeBio Pharma Inc2026 Big Picture & AI Powered Market Entry Ideas - baoquankhu1.vn
Market Rankings: Will BridgeBio Pharma Inc benefit from green energy policies2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
BridgeBio Pharma, Inc. (BBIO) Stock forecasts - Yahoo Finance UK
BBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - Moomoo
BridgeBio to present LGMD2I/R9 trial data at MDA conference By Investing.com - Investing.com India
Viking funds hold 6.1% of BridgeBio Pharma (NASDAQ: BBIO) - Stock Titan
BridgeBio to present LGMD2I/R9 trial data at MDA conference - Investing.com
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), 60 Degrees Pharmaceuticals, Inc. (SXTP) and BridgeBio Pharma (BBIO) - The Globe and Mail
Bond Watch: Is BridgeBio Pharma Inc stock a value trapEarnings Trend Report & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Allspring Global Investments Holdings LLC Has $77.78 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
Sentiment Review: Will BridgeBio Pharma Inc benefit from green energy policies2026 Biggest Moves & Low Volatility Stock Recommendations - baoquankhu1.vn
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why - Insider Monkey
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Bridgebio asks FDA to approve potential 1st treatment for LGMD2i - Muscular Dystrophy News
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $111 - Moomoo
BridgeBio's rare-disease pipeline sparks growth buzz - MSN
INVESCO Small Cap Equity Fund's BridgeBio Pharma Inc(BBIO) Holding History - GuruFocus
Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio submits NDA for oral BBP-418 to treat LGMD2I/R9 - Investing.com Australia
BridgeBio Files NDA for LGMD2I/R9 Oral Therapy - TipRanks
BridgeBio (BBIO) Shares Promising Long-Term Acoramidis Data at A - GuruFocus
BridgeBio (BBIO) Submits Application for New Muscular Dystrophy Treatment - GuruFocus
BridgeBio (NASDAQ: BBIO) files NDA for first potential LGMD2I/R9 treatment - stocktitan.net
BridgeBio reports sustained mortality benefits for acoramidis at 54 months By Investing.com - Investing.com Canada
BridgeBio Pharma Announces Sustained Clinical Benefits of Acoramidis in Long-Term ATTRibute-CM Trial - Quiver Quantitative
BridgeBio Pharma, Inc. Presents Long-Term Efficacy and Safety Data from the ATTRibute-CM Open-Label Extension Trial - marketscreener.com
Jefferies reiterates Buy on BridgeBio Pharma stock, $100 target By Investing.com - Investing.com Canada
BridgeBio submits NDA to FDA for BBP-418 for individuals living with LGMD2I/R9 - marketscreener.com
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - manilatimes.net
BridgeBio Pharma stock drops 3.97% as NDA filed with FDA for BBP-418 therapy - Traders Union
5 High Growth Healthcare Stocks to Buy Now - Insider Monkey
BridgeBio Pharma stock price forecast: mixed signals as BBIO retreats 3.97% toward key support - Traders Union
Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative? - Yahoo Finance
BridgeBio Pharma (MIL:1BBIO) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
(BBIO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Phase III wins lift shares of Compass, Palvella and Bridgebio in February - BioWorld News
Vanguard disaggregates holdings; reports 0 Bridgebio shares (BBIO) - Stock Titan
Returns Recap: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEAR - baoquankhu1.vn
Market Catalysts: Whats next for BridgeBio Pharma Inc stock2026 Technical Overview & Fast Gaining Stock Reports - baoquankhu1.vn
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.57%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):